Anti-obesity Pharmacotherapy in Prediabetes to Prevent T2D
Anti-obesity Pharmacotherapy in Prediabetes to Prevent T2D
A number of novel treatments are currently being evaluated in patients with obesity/prediabetes and are discussed below.
GLP-1 analogs and GLP-1 RAs in clinical development include semaglutide.
The gut hormone peptide YY (PYY) is coreleased with GLP-1 after meals. Co-administration of synthetic PYY3–36 and GLP-117–36amide modulates activity in areas of the brain associated with appetite control, producing an anorectic effect. This makes PYY a potentially interesting target for future evaluation in clinical studies of obese individuals.
Another compound in development for the management of diabetes is ITCA 650, a miniature osmotic pump system designed to provide continuous subcutaneous delivery of exenatide. A Phase II study of ITCA 650 has demonstrated improvements in glycemic control coupled with weight loss over 48 weeks in patients with type 2 diabetes, with potential advantages including patient convenience and ease of use. A press release reports similar findings from 2 Phase III studies of ITCA 650; these data are expected to be published at the 2015 ADA meeting.
Agents Undergoing Clinical Development for the Treatment of Obesity/Prediabetes
A number of novel treatments are currently being evaluated in patients with obesity/prediabetes and are discussed below.
GLP-1 Analogs/GLP-1 RAs
GLP-1 analogs and GLP-1 RAs in clinical development include semaglutide.
Peptide YY
The gut hormone peptide YY (PYY) is coreleased with GLP-1 after meals. Co-administration of synthetic PYY3–36 and GLP-117–36amide modulates activity in areas of the brain associated with appetite control, producing an anorectic effect. This makes PYY a potentially interesting target for future evaluation in clinical studies of obese individuals.
ITCA 650
Another compound in development for the management of diabetes is ITCA 650, a miniature osmotic pump system designed to provide continuous subcutaneous delivery of exenatide. A Phase II study of ITCA 650 has demonstrated improvements in glycemic control coupled with weight loss over 48 weeks in patients with type 2 diabetes, with potential advantages including patient convenience and ease of use. A press release reports similar findings from 2 Phase III studies of ITCA 650; these data are expected to be published at the 2015 ADA meeting.